Expectedly, shed syndecan-2-containing serum samples from patients were found to significantly enhance migration of HCT116 colon cancer cells compared to cells treated with serum samples with lower levels of shed syndecan-2 and depletion of shed syndecan-2 from the serum abolished the increased migration and anchorage-independent growth of colon cancer cells (Figure 5D). Here, SDC2 is linked to malignant colon neoplasm.